COVID-19 with Different Severities: A Multicenter Study of Clinical Features
Open Access
- 1 June 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 201 (11), 1380-1388
- https://doi.org/10.1164/rccm.202002-0445oc
Abstract
Rationale: COVID-19 pandemic is now a global health concern. Objectives: We compared the clinical characteristics, laboratory examinations, CT images and treatment of COVID-19 patients from three different cities in China. Methods: 476 patients were recruited from Jan 1 to Feb 15, 2020 at three hospitals in Wuhan, Shanghai and Anhui. Patients were divided into four groups according to age and into three groups (moderate, severe, and critical group) according to the fifth version of the guidelines issued by the National Health Commission of China on Diagnosis and Treatment of COVID-19. Measurements and main results: Compared with moderate group (37.8%), the incidence of comorbidities was higher in severe (46.3%) and critical groups (67.1%). Compared with severe and critical groups, there were more patients taking ACEI/ARB in moderate group. More patients had multiple lung lobe involvement and pleural effusion in the critical group as compared to moderate group. Compared with the moderate group, more patients received antiviral agents within first 4 days than in severe group, and more patients received antibiotics and corticosteriods in critical and severe groups. Patients over 75 years old had significantly lower survival rate than the younger patients. Conclusion: Multiple organ dysfunction and impaired immune function were the typical characteristics of severe and critical patients. There was a significant difference in angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers usage among patients with different severities. Involvement of multiple lung lobes and pleural effusion were associated with the severity of COVID-19. Advanced age (≥75 years) was a risk factor for mortality. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords
This publication has 23 references indexed in Scilit:
- Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2014
- Severity assessment tools in ICU patients with 2009 Influenza A (H1N1) pneumoniaClinical Microbiology & Infection, 2012
- Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptorProceedings of the National Academy of Sciences of the United States of America, 2009
- The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2Virology, 2007
- The Radiologic Manifestations of H5N1 Avian InfluenzaJournal of Thoracic Imaging, 2006
- Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARSThe Journal of Pathology, 2006
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Journal of the American College of Cardiology, 2005
- Significant Changes of Peripheral T Lymphocyte Subsets in Patients with Severe Acute Respiratory SyndromeThe Journal of Infectious Diseases, 2004
- Expression of Lymphocytes and Lymphocyte Subsets in Patients with Severe Acute Respiratory SyndromeClinical Infectious Diseases, 2003
- Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysisBMJ, 2003